Instability at simple repetitive DNA sequences has been observed in a subset of sporadic colorectal cancers (1, 2) and in essentially all tumors from patients with hereditary nonpolyposis colorectal cancer (HNPCC) (3) (4) (5) . Deficiency in binding and repair of DNA mismatches has been demonstrated in tumor cell lines exhibiting such instability (6) (7) (8) (9) (10) , and studies show an increased spontaneous mutation rate in selectable genes (8, (11) (12) (13) . In most HNPCC tumors and in many of the sporadic cases, the underlying basis of this mutator or RER (replication error) phenotype is mutational inactivation of a human mismatch repair gene, five of which have so far been described (10, (14) (15) (16) (17) (18) . With the exception of GTBP/pl60 (19) , germ-line mutations have been identified in each of these genes in HNPCC families (5, 15-18, 20, 21) . However, mismatch repair gene mutations can only be detected in about half of sporadic colorectal tumors that exhibit an RER phenotype (19, 22, 23) , suggesting that other genes may also contribute to genetic instability in the nonfamilial cases.
A substantial proportion of RER cell lines have inactivating mutations in the type (3 transforming growth factor (TGF-,B)
receptor 11 (24, 25) , but there are little other data on the role of defective mismatch repair (MMR) in the generation of mutations in genes that are specifically implicated in tumorigenesis. In this study, we sought to investigate the influence of genetic instability on the frequency and the spectrum of APC (adenomatous polyposis coli) gene mutations in colorectal tumors. Mutational inactivation of the APC gene appears to initiate colorectal tumorigenesis, not only in mice and humans with germ-line alterations ofAPC, but also in patient populations with sporadic colorectal neoplasia. Hence it is of considerable interest to determine the nature of processes that may be responsible for the development of such mutations. Here, we show a striking relationship in colorectal tumors between the APC mutational spectrum and the presence of genetic instability manifest as the RER phenotype. Our findings provide insight into mechanisms by which defective DNA mismatch repair leads to the development of cancer in humans and demonstrate that such mismatch repair deficiency has important influence from the very earliest stages of tumorigenesis in the colorectal epithelium.
MATERIALS AND METHODS
Collection of Clinical Material and Template Preparation. All patients had undergone resection of histologically verified colorectal adenomas or carcinomas. Familial adenomatous polyposis cases were excluded. The following criteria had to be fulfilled for assignment as an HNPCC case: three first-degree relatives affected by pathologically confirmed colorectal cancer, one affected case arising under 50 years of age, one affected case to be the first-degree relative of the other two, and two or more affected generations (26) .
Fresh tumor samples were from patients with colorectal neoplasms undergoing surgery in Edinburgh Royal Infirmary or The Johns Hopkins Hospital. Cell lines were derived from colorectal cancers as described (27) or from American Type Culture Collection and were passaged either in nude mice or in vitro. DNA and RNA were purified from peripheral blood leukocytes, fresh tumor tissue, adjacent normal colonic mucosa, cell lines, and xenografts by standard protocols. For RER and APC mutation analysis of primary tumors, constitutional RNA and DNA were compared with that prepared from fresh tumor tissue taken from cryostat sections (28) (25, 29, 30) . To be categorized -as RER, tumors were required to demonstrate variations compared with control tissue in at least half of the markers tested. Following electrophoresis on denaturing gels containing formamide, alleles were visualized either by silverstaining (31), autoradiography of radiolabeled products, or by analysis of fluorescent labeled products using a Pharmacia Proc. Natl. Acad. Sci. USA 93 (1996) automated laser fluorescence (ALF) automated sequencer and the manufacturer's software.
APC Mutation Screening Strategy. Screening for APC gene mutations was performed by an in vitro synthesized protein assay (IVSP) which allows detection of truncated surrogate APC protein products as described (32) (33) (34) . In brief, IVSP involved PCR amplification of 100-200 ng of DNA or cDNA by using PCR primers to introduce a 17-bp consensus T7 promoter sequence and a mammalian translation initiation sequence in frame with unique APC sequence. PCR primer-pair sequences and PCR conditions are available on request and are similar to those previously described (32) . For exons 1-14 (segment 1), cDNAwas produced by reverse transcription of tumor RNA followed by PCR amplification (32, 33 In 28 cell lines, truncating mutations were identified by using Western blots instead of IVSP assays, performed with monoclonal antibody FE9, as described (35) . In 20 of these lines, the presence or absence of truncated APC had been reported previously (35) .
DNA or cDNA from tumors with reproducible truncations were subjected to independent amplification. PCR fragments were purified and sequenced by using Sequenase 2 (United States Biochemical) with 35S-labeled dATP or SequiTherm polymerase (Epicentre Technologies, Madison, WI) with 32p_ labeled primers. Termination of the reactions was followed by electrophoresis in 6% acrylamide under denaturing conditions. Dried sequencing gels were exposed to XAR (Kodak) film overnight.
RESULTS
Prevalence of Truncating APC Mutations in RER Tumors. To allow meaningful assessment of the prevalence of APC mutations in RER tumors, we analyzed a sufficient number of primary tumors and cell lines to identify a relatively large number of RER cases. In all, 52 RER tumors were identified for mutation analysis of theAPC gene by combining 20 tumors from a new prospective cohort with 32 tumors identified in our previous studies of genetic instability (3, 5, 6, 22, 25) . Nineteen of these 52 tumors were derived from patients who were members of different HNPCC kindreds, and the remainder were not associated with any known family history of colorectal cancer. Sixty-three non-RER tumors were selected randomly from the 412 sporadic tumors analyzed to acquire the 52 RER cases. The fraction of RER tumors among the total sporadic cases examined (15.8%) was similar to that reported in previous studies (1-3, 36, 37) . Examples of the microsatellite assays employed for determination of RER status are shown in Fig. 1 .
Screening for truncating APC mutations was performed on the 115 tumors in the combined RER groups by using either IVSP assays (32) (33) (34) or Western blots (35) as described. Both assays are highly reliable indicators ofAPC mutation status, as virtually all pathogenic APC mutations result in truncated proteins (38) . Examples of positive IVSP assays are shown in Fig. 2 . The prevalence of truncated APC gene product detectable by our assays was somewhat lower in the RER tumors (29 
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N. (1996) proved to be from RER tumors and the remaining 40 from non-RER cases.
A comparison of the nature and location of the whole set of 101 APC mutations in RER and non-RER tumors is presented in Table 3 . There were a number of striking differences in the mutation spectrum between the two RER tumor categories. A substantial excess of frameshift mutations in the RER tumors was observed: 70% of the mutations in RER tumors were insertions or deletions, while only 47% of the mutations in the non-RER tumors were of this type (P < 0.04, X = 4.3; Table   3 ). The excess of frameshift mutations was observed in both HNPCC (8 of 12; 75%) and sporadic tumors (14 of 20; 70%) exhibiting the RER phenotype.
Most of the insertions or deletions in the RER tumors were within simple repeated sequences (Table 1 and 3) . Twenty-one of 26 (81%) frameshift mutations in RER tumors occurred within such microsatellites, compared with only 11 of 30 (37%) in non-RER tumors (P < 0.003, X = 9.33). Mutations within (A)n tracts were especially prominent in the RER tumors, accounting for 49% of allAPC mutations detected in RER tumors, while only Proc. Natl. Acad. Sci. USA 93 (1996) 9053 11% of the mutations in non-RER cases were of this type (P < 0.00007, X2 = 15.93). The complete lack of deletion or insertion of more than 2 bp in RER tumors was also notable.
Point mutations were accordingly less frequent in the RER cases (30%) than in the non-RER cases (53%). In contrast to the frameshifts noted above, the targets for point mutation were largely similar in the two RER groups. Although there was a tendency for transitions rather than transversions in the RER tumors, this difference was not statistically significant (Table 3 ). All point mutations identified in RER tumors occurred at C:G base pairs and all but one resulted in C --T changes (Tablel and 3). In both the RER and non-RER cases, CpG dinucleotides seemed to be the favored mutation sites, being affected in 8 of 11 (73%) and 15 of 34 (44%) of the point mutations in RER and non-RER tumors, respectively (P = not significant) (Tables 1 and 2 ).
DISCUSSION
Two major conclusions can be drawn from this study. First, APC mutations occur in the majority of RER and of non-RER tumors, suggesting that both tumor types proceed along a similar pathogenetic pathway. Second, the APC mutational spectrum is substantially different in RER tumors from that in non-RER tumors. This observation provides additional evidence that genetic instability is not simply an epiphenomenon associated with tumorigenesis, but has a direct, causal role in colorectal neoplasia.
Many previous observations indicate that mutational inactivation ofAPC plays a central role in colorectal tumorigenesis. Gene carriers from familial adenomatous polyposis families and mice with heritable mutations of APC develop numerous colorectal and small intestinal tumors (38, (43) (44) (45) . Truncation or complete absence of APC protein can be demonstrated in the great majority of colorectal tumors (38, 40, 42, (46) (47) (48) . Such mutations can be detected in the smallest adenomas studied (40, (46) (47) (48) as well as in dysplastic aberrant crypt foci, which appear to be the very earliest histological manifestation of neoplasia (41, 49) . In light of the differences in genetic instability and other features characteristic of RER compared with non-RER tumors, it was possible that the molecular pathogenesis of these two tumor types differed considerably. Indeed, TGF-P receptor II mutations have been identified exclusively in RER cases (24, 25) . However, the data presented here demonstrate that a critical and probably initiating step in colorectal neQplasia, namely APC mutation, is common to both tumor types. Data from other studies indicate that ras and p53 mutations also occur in both tumor types (1, 3, 50) , although larger studies will be needed to better quantify the relative prevalence and spectra of these alterations. The clinical and biological differences that exist between RER and non-RER tumors may result from genetic alterations that occur exclusively in RER cases, such as those demonstrated in the TGF-3 receptor (24, 25) , although host factors are also likely to play a part.
Genome-wide mutations at (A)n tracts are common in colorectal cancers exhibiting a mutator phenotype (1) , and the data presented here demonstrate a direct link between such genetic instability and cancer gene mutations. The reason why (A)n tract mutations were more common than dinucleotide repeat alterations likely involves the relative frequency of mononucleotide and dinucleotide repeats withinAPC. For example, runs of three or more (CA), (AT), (AG), or (TG) dinucleotide repeats occur 3, 2, 8, and 1 times, respectively, within the entire APC coding sequence compared with 278 runs of (A).23, 103 runs of (A)u4 and 33 runs of (A)s5. The relatively high frequency of (A)n tracts within the APC gene may in part explain the tumor spectrum arising in HNPCC patients. We hypothesize that genes involved in the initiation of tumors that are common in HNPCC, such as colorectal and uterine cancers, may be prone to mutation because of a higher frequency of microsatellites within their coding sequence. Thus, the initiating role of inactivatingAPC mutations in colorectal tumorigenesis and a corresponding relative abundance of microsatellite sequences in the APC coding sequence may be analogous to the situation in uterine cancer, for which the initiating gene remains, as yet, uncharacterized. In contrast, such microsatellites may be rare in genes involved in the initiation of lung cancer, which is not part of the HNPCC tumor spectrum. A lower frequency of (A)n tracts in the murine APC sequence may also partly explain the absence of colon tumors in transgenic mice with homozygous defects in mismatch repair genes (51, 52) . Runs of 3,4, and 5 (A)n repeats are 25%, 43%, and 32% more common, respectively, in the human than in the murine APC sequence.
Interestingly, in TGF-(3 receptor II, the only other gene identified so far as a specific target for mutation in RER tumors, the microsatellite content differs considerably between the human and mouse homologs. The (A)1o tract in the human sequence that is mutated in 90% of RER colorectal tumors (24, 25) is completely absent from the mouse homolog.
The predominance of -1 or + 1 frameshifts in RER tumors and the complete absence of deletions or insertions involving more than 1 bp in tumors with mismatch repair gene mutations indicates either that larger replication slippages do not occur in the APC gene or that they are efficiently repaired by other mechanisms. Indeed the only frameshift mutations of more than 2 bp noted in this study were in non-RER tumors.
An excess of A:T transversions or -2 deletions has been noted previously in the aprt gene in a clone of CHO cells with a mutator phenotype and defective mismatch binding (8, 11) , but this was not apparent in RER tumors in this study. However, observations in a variety of cell lines indicate that the mutator phenotype is a heterogeneous phenomenon with substantial variation between cell lines in both mutation rate and in the type of mutation that arises (12, 13, 19, 53) . Hence, detailed analysis of a large series of primary tumors, such as reported here, allows independent determination of the effect of genetic instability on mutations in genes known to be involved in tumorigenesis and is a robust method of assessing its relevance in an in vivo human context.
Mismatch repair capacity is intact in normal tissues of most HNPCC patients because of the presence of the relevant wildSummary data on the 101 APC gene mutations characterized by sequencing, comparing the mutational spectrum and target sequences in RER tumors with those in non-RER tumors.
*p < 0.04; tP < 0.0002; 1P < 0.00007; §P < 0.0003. 
